[1] GBD 2017 Cirrhosis Collaborators. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol,2020,5(3): 245-266.
[2] Zeng X,Shi ZW,Yu JJ,et al. Sarcopenia as a prognostic predictor of liver cirrhosis: a multicentre study in China. J Cachexia Sarcopenia Muscle,2021,12(6):1948-1958.
[3] Baumgartner RN. Body composition in healthy aging. Ann N Y Acad Sci,2000,904:437-448.
[4] Kim TN,Choi KM. The implications of sarcopenia and sarcopenic obesity on cardiometabolic disease. J Cell Biochem,2015,116(7):1171-1178.
[5] Tian S, Xu Y. Association of sarcopenic obesity with the risk of all-cause mortality: a meta-analysis of prospective cohort studies. Geriatr Gerontol Int,2016,16(2):155-166.
[6] Eslamparast T,Montano-Loza AJ,Raman M,et al. Sarcopenic obesity in cirrhosis-the confluence of 2 prognostic titans. Liver Int,2018,38(10):1706-1717.
[7] Cleasby ME,Jamieson PM,Atherton PJ. Insulin resistance and sarcopenia: mechanistic links between common co-morbidities. J Endocrinol,2016,229(2):R67-R81.
[8] Bojko M. Causes of sarcopenia in liver cirrhosis.Clin Liver Dis (Hoboken),2019,14(5):167-170.
[9] Zhao M,Zhou X,Yuan C, et al. Association between serum irisin concentrations and sarcopenia in patients with liver cirrhosis: a cross-sectional study. Sci Rep,2020,10(1):16093.
[10] Nishikawa H,Enomoto H,Ishii A,et al. Elevated serum myostatin level is associated with worse survival in patients with liver cirrhosis. J Cachexia Sarcopenia Muscle,2017,8(6):915-925.
[11] Merli M,Lattanzi B,Aprile F. Sarcopenic obesity in fatty liver. Curr Opin Clin Nutr Metab Care,2019,22(3):185-190.
[12] Montano-Loza AJ,Angulo P,Meza-Junco J,et al. Sarcopenic obesity and myosteatosis are associated with higher mortality in patients with cirrhosis. J Cachexia Sarcopenia Muscle,2016,7(2):126-135.
[13] Kobayashi A,Kaido T,Hamaguchi Y, et al. Impact of sarcopenic obesity on outcomes in patients undergoing hepatectomy for hepatocellular carcinoma. Ann Surg,2019,269(5):924-931.
[14] Carias S,Castellanos AL,Vilchez V,et al. Nonalcoholic steatohepatitis is strongly associated with sarcopenic obesity in patients with cirrhosis undergoing liver transplant evaluation. J Gastroenterol Hepatol,2016,31(3):628-633.
[15] Chen CJ,Wang LC,Kuo HT,et al. Significant effects of late evening snack on liver functions in patients with liver cirrhosis: a meta-analysis of randomized controlled trials. J Gastroenterol Hepatol,2019,34(7):1143-1152.
[16] Amodio P,Bemeur C, Butterworth R, et al. The nutritional management of hepatic encephalopathy in patients with cirrhosis: International Society for Hepatic Encephalopathy and Nitrogen Metabolism Consensus. Hepatology,2013,58(1):325-336.
[17] Chalasani N,Younossi Z,Lavine JE,et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology,2018,67(1):328-357.
[18] Liao CD,Tsauo JY, Lin LF,et al. Effects of elastic resistance exercise on body composition and physical capacity in older women with sarcopenic obesity: a CONSORT-compliant prospective randomized controlled trial. Medicine (Baltimore),2017,96(23):e7115.
[19] Dieli-Conwright CM,Courneya KS,Demark-Wahnefried W, et al.Effects of aerobic and resistance exercise on metabolic syndrome, sarcopenic obesity, and circulating biomarkers in overweight or obese survivors of breast cancer: a randomized controlled trial. J Clin Oncol,2018,36(9):875-883.
[20] Macías-Rodríguez RU,Ruiz-Margáin A,Román-Calleja BM, et al.Exercise prescription in patients with cirrhosis: recommendations for clinical practice. Rev Gastroenterol Mex (Engl Ed),2019,84(3):326-343.
[21] Kumar A,Davuluri G,Silva RNE,et al. Ammonia lowering reverses sarcopenia of cirrhosis by restoring skeletal muscle proteostasis. Hepatology,2017,65(6):2045-2058.
[22] Consitt LA,Clark BC. The vicious cycle of myostatin signaling in sarcopenic obesity: myostatin role in skeletal muscle growth, insulin signaling and implications for clinical trials. J Frailty Aging,2018,7(1):21-27.
[23] Santos AR,Lamas L,Ugrinowitsch C, et al. Different resistance-training regimens evoked a similar increase in myostatin inhibitors expression. Int J Sports Med,2015,36(9):761-768.
[24] Huang Y,Zhu X,Chen K, et al. Resveratrol prevents sarcopenic obesity by reversing mitochondrial dysfunction and oxidative stress via the PKA/LKB1/AMPK pathway. Aging (Albany NY),2019,11(8):2217-2240.
[25] Shin JE,Jeon SH,Lee SJ,et al.The administration of panax ginseng berry extract attenuates high-fat-diet-induced sarcopenic obesity in C57BL/6 mice. Nutrients,2022,14(9):1747.
[26] Sinclair M,Grossmann M,Hoermann R,et al.Testosterone therapy increases muscle mass in men with cirrhosis and low testosterone: a randomised controlled trial. J Hepatol,2016,65(5):906-913.
[27] Lattanzi B,Bruni A,Di Cola S,et al.The effects of 12-week beta-hydroxy-beta-methylbutyrate supplementation in patients with liver cirrhosis: results from a randomized controlled single-blind pilot study. Nutrients,2021,13(7):2296.
[28] Agarwal L,Sahu AK,Baksi A,et al. Safety of metabolic and bariatric surgery in obese patients with liver cirrhosis: a systematic review and meta-analysis. Surg Obes Relat Dis,2021,17(3):525-537.
[29] Cazzo E,Gestic MA,Utrini MP,et al.Bariatric surgery in individuals with liver cirrhosis: a narrative review. Rev Assoc Med Bras (1992),2017,63(2):190-194.
[30] Patton H, Heimbach J, McCullough A. AGA clinical practice update on bariatric surgery in cirrhosis: expert review. Clin Gastroenterol Hepatol,2021,19(3):436-445. |
